07 Dec 2022
30 Nov 2022
The study's goal is to highlight the importance of contrast enhanced spectral mammography (CESM) in assessing response of breast cancer to neoadjuvant chemotherapy (NAC) in terms of residual tumor size and extent. CESM was performed on thirty female patients with ages between 30 and 57 years old, diagnosed as malignant breast cancer and planned to receive NAC. To ensure the final diagnosis of residual masses and to determine the specificity and sensitivity of CESM, the final histopathology and/or at least 6 months of clinical and radiological follow-up were employed as reference standards. In current study, the enrolled subjects underwent both contrast enhanced spectral mammography (CESM) and conventional full field digital mammography (FFDM) before and after neoadjuvant chemotherapy (NAC) and prior to surgery and results were compared to final pathological response. CESM was shown to be better than FFDM in terms of sensitivity, specificity, and accuracy, measuring 71.4 %, 100% and 90% for (CESM), compared to 56%, 75% and 75% for (FFDM). Contrast-enhanced spectral mammography is a growing technique showing high accuracy in monitoring response of breast cancer to NAC regarding tumor residual size and extent so that the physician can make the optimal therapy decision.